In our study, we observed that the overall signals at the SOC level were stronger for panitumumab compared to cetuximab in skin and subcutaneous tissue systems (ROR: 3.9 vs. 2.59), including rash (ROR: 5.97 vs. 4.76), dermatitis acneiform (ROR: 258.74 vs. 132.56), skin toxicity (ROR: 198.52 vs. 34.66) and dry skin (ROR: 5.79 vs. 3.05). The gene discussed is UBXN11; the disease is Dry skin.